We require masks in our office regardless of COVID-19 vaccination status.
Telehealth available for follow-up as well as new consultations. Please contact us Here
1-818-812-7222 Office Hours: 8:00 AM to 5:00 PM
10 Congress St., Suite #405
Pasadena, CA 91105

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

Link to Scientific Article :
The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

Date of Publication: April 2020

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) causes significant mortality. It is therefore important to minimize the inflammatory response.